Jounce Therapeutics, an early-stage biotech developing T cell immuno-oncology therapies with Celgene, raised $104 million by offering 6.5 million shares at $16, above the range of $13 to $15. Jounce Therapeutics plans to list on the Nasdaq under the symbol JNCE. J.P. Morgan and Cowen & Company acted as lead managers on the deal.
The article Jounce Therapeutics prices upsized IPO at $16 to advance cancer immunotherapies with Celgene originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.